'Delisting of NCD's from BSE'
As filed · Onesource Specialty Pharma Limited has informed the Exchange regarding 'Delisting of NCD's from BSE'.
What happened
FactOnesource Specialty Pharma Limited has informed the Exchange regarding 'Delisting of NCD's from BSE'. for their delisting from BSE Limited on June 05, 2025. The delisting application was approved by the Exchange and.
Why it matters
CapitSignal interpretationDelisting removes the ability to sell on the exchange, so the discovered exit price becomes the only liquidity event.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
DelayedEBITDA at ₹173 million, down 88% YoY, due to lower revenue in the quarter and largely fixed cost base
EBITDA has also come in at INR1,233 million, which has been up significantly, 39% year-on-year, as well as sequentially 34% versus last quarter, and which has been in line when we have said last time that we will be showing a sequential quarter-on-quarter growth.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Floor price and the discovered price
- Whether the offer succeeds at the threshold
- you will see, this addition will be a significant contributor to our FY28 numbers (management committed by FY28)
- $400 million in organic revenue with 40% EBITDA margin (management committed by FY28)
Evidence
- Onesource Specialty Pharma Limited has informed the Exchange regarding 'Delisting of NCD's from BSE'.(opens the original filing in a new tab)
- Earlier statement · Q3 FY26
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- DELISTING base 70; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%